AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6385931 — intervention group
Group type: EXPERIMENTAL
Intervention: Both topical indomethacin and dexamethasone
Number of subjects: 283
Study 6385931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283
Study 6385931 — intervention group
Group type: COMPARATOR
Intervention: Both placebos
Number of subjects: 283
Study 30074109 — intervention group
Group type: EXPERIMENTAL
Intervention: LED-LLLT (830/590 nm) applied after fractional CO2 laser treatment on one side of the face
Number of subjects: 36
Study 30074109 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO2 only) without LED-LLLT
Number of subjects: 36
Study 30514062 — intervention group
Group type: EXPERIMENTAL
Intervention: WeChat alcohol education lessons (3 lessons over 2 weeks)
Number of subjects: 0
Study 30514062 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study 27589510 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (atDCS) combined with robot-assisted arm training (R-AAT)
Number of subjects: 9
Study 27589510 — intervention group
Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation (stDCS) combined with robot-assisted arm training (R-AAT)
Number of subjects: 9
Study 24650022 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (75 mL, 150 mg)
Number of subjects: 53
Study 24650022 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 53
Study 22527091 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 1559
Study 22527091 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and physical functioning
Number of subjects: 1559
Study 22527091 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications
Number of subjects: 1559
Study 22527091 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender adjusted for age and physical functioning
Number of subjects: 1559
Study 20299077 — intervention group
Group type: EXPERIMENTAL
Intervention: Totally tubeless PCNL (group 1)
Number of subjects: 60
Study 20299077 — intervention group
Group type: COMPARATOR
Intervention: Standard PCNL with nephrostomy tube (group 2)
Number of subjects: 60
Study 17975791 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 weeks of treatment with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily
Number of subjects: 428
Study 17975791 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of treatment with pegylated interferon alpha-2b (1.5 microg/kg) subcutaneously weekly and ribavirin (800-1400 mg) orally daily
Number of subjects: 428
Study 11679827 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtransverse wiring technique
Number of subjects: 12
Study 9135733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic liposomes with plasmid containing human CFTR cDNA (administered to 8 patients)
Number of subjects: 12
Study 9135733 — intervention group
Group type: COMPARATOR
Intervention: Placebo (administered to 4 patients)
Number of subjects: 12
Study 9135733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cationic liposomes with plasmid containing human CFTR cDNA
Number of subjects: 12
Study 7698130 — intervention group
Group type: EXPERIMENTAL
Intervention: Trandolapril (ACE inhibitor)
Number of subjects: 7001
Study 7698130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7001
Study 3656112 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzphetamine (25 and 50 mg)
Number of subjects: 0
Study 3656112 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenmetrazine (25 and 50 mg)
Number of subjects: 0
Study 3656112 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol (0.5, 1.0 and 2.0 mg)
Number of subjects: 0
Study 3656112 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylpropanolamine (12.5, 25 and 50 mg)
Number of subjects: 0
Study 3656112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31020673 — intervention group
Group type: EXPERIMENTAL
Intervention: Susceptibility-guided therapy (esomeprazole 20 mg, amoxicillin 1 g b.d., clarithromycin 500 mg, metronidazole 400 mg b.d., or levofloxacin 500 mg daily for susceptible infections; bismuth 220 mg b.d. and metronidazole 400 mg q.d.s. for triple-resistant infections)
Number of subjects: 382
Study 31020673 — intervention group
Group type: COMPARATOR
Intervention: Empiric therapy (esomeprazole 20 mg, bismuth 220 mg b.d., amoxicillin 1 g, metronidazole 400 mg t.d.s.)
Number of subjects: 382
Study 28285844 — intervention group
Group type: EXPERIMENTAL
Intervention: 4400 international units/d vitamin D
Number of subjects: 712
Study 28285844 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus 400 international units/d vitamin D
Number of subjects: 712
Study 25142041 — intervention group
Group type: EXPERIMENTAL
Intervention: PortionControl@HOME intervention
Number of subjects: 278
Study 23299011 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual risk-reduction (SRR) intervention
Number of subjects: 738
Study 23299011 — intervention group
Group type: COMPARATOR
Intervention: Health promotion control group
Number of subjects: 738
Study 21619593 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography and Doppler evaluation of hemodynamic patterns
Number of subjects: 922
Study 17602235 — intervention group
Group type: EXPERIMENTAL
Intervention: Brückner test at 1 m
Number of subjects: 5
Study 17602235 — intervention group
Group type: EXPERIMENTAL
Intervention: Brückner test at 4 m
Number of subjects: 5
Study 17602235 — intervention group
Group type: EXPERIMENTAL
Intervention: Brückner test at 1 m for unilateral astigmatism
Number of subjects: 5
Study 17602235 — intervention group
Group type: EXPERIMENTAL
Intervention: Brückner test at 4 m for unilateral astigmatism
Number of subjects: 5
Study 17602235 — intervention group
Group type: COMPARATOR
Intervention: Brückner test at 1 m (false positives)
Number of subjects: 5
Study 17602235 — intervention group
Group type: COMPARATOR
Intervention: Brückner test at 4 m (false positives)
Number of subjects: 5
Study 16595220 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (triptorelin)
Number of subjects: 32
Study 16595220 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix)
Number of subjects: 32
Study 12671890 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA‐985 100 mg/day
Number of subjects: 60
Study 12671890 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA‐985 200 mg/day
Number of subjects: 60
Study 12671890 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 11022985 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 800 microg daily
Number of subjects: 113
Study 11022985 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 1600 microg daily
Number of subjects: 113
Study 11022985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 9192235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine at 1.0 microgram/kg per min (Group 1, n = 19)
Number of subjects: 67
Study 9192235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine at 2.0 micrograms/kg per min (Group 2, n = 15)
Number of subjects: 67
Study 9192235 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine at 3.0 micrograms/kg per min (Group 3, n = 19)
Number of subjects: 67
Study 1584644 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional orthotic therapy (CALIGAMED splint)
Number of subjects: 0
Study 1584644 — intervention group
Group type: COMPARATOR
Intervention: Operative treatment
Number of subjects: 0
Study 29343449 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5g TXA in 100mL normal saline solution (IA group, n=58)
Number of subjects: 113
Study 29343449 — intervention group
Group type: COMPARATOR
Intervention: 10mg/kg TXA (IV group, n=55)
Number of subjects: 113
Study 29343449 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5g TXA in 100mL normal saline solution (IA group)
Number of subjects: 113
Study 29343449 — intervention group
Group type: COMPARATOR
Intervention: 10mg/kg TXA (IV group)
Number of subjects: 113
Study 29343449 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IA and IV groups
Number of subjects: 113
Study 27039081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide LAR 40 mg/28 days
Number of subjects: 119
Study 27039081 — intervention group
Group type: COMPARATOR
Intervention: Octreotide LAR 20 mg/28 days
Number of subjects: 119
Study 25636157 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplemented with omega-3 fatty acids for 12 weeks
Number of subjects: 0
Study 25636157 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cholecalciferol only) for 12 weeks
Number of subjects: 0
Study 23533244 — intervention group
Group type: EXPERIMENTAL
Intervention: Methane and hydrogen positive (M+/H+)
Number of subjects: 792
Study 23533244 — intervention group
Group type: COMPARATOR
Intervention: Normal (N)
Number of subjects: 792
Study 23533244 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen positive only (H+)
Number of subjects: 792
Study 23533244 — intervention group
Group type: COMPARATOR
Intervention: Methane positive only (M+)
Number of subjects: 792
Study 20495498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular radiation therapy (IVRT) using Re-188 filled balloon, 18 Gy dose at 0.5 mm depth, after successful coronary angioplasty
Number of subjects: 39
Study 20495498 — intervention group
Group type: COMPARATOR
Intervention: Control group (no IVRT)
Number of subjects: 39
Study 18294549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond (2-octylcyanoacrylate)
Number of subjects: 40
Study 18294549 — intervention group
Group type: COMPARATOR
Intervention: Suture repair (6-0 chromic suture)
Number of subjects: 40
Study 18294549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond
Number of subjects: 40
Study 18294549 — intervention group
Group type: COMPARATOR
Intervention: Suture repair
Number of subjects: 40
Study 17309153 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (CT) - 4 patients, 4-6 cycles
Number of subjects: 15
Study 17309153 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy/Radiotherapy (CT/RT) - 8 patients, 1-2 cycles of CT before RT and 4 cycles after RT
Number of subjects: 15
Study 17309153 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) - 3 patients, external beam radiotherapy (EBRT), total dose 45 Gy, 24 fractions
Number of subjects: 15
Study 17309153 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) across all therapy groups
Number of subjects: 15
Study 17309153 — intervention group
Group type: COMPARATOR
Intervention: Late complications
Number of subjects: 15
Study 17309153 — intervention group
Group type: COMPARATOR
Intervention: Time to relapse
Number of subjects: 15
Study 15382668 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Support System (DSS) based on an artificial neural network for MAC diagnosis
Number of subjects: 61
Study 15382668 — intervention group
Group type: COMPARATOR
Intervention: Expert subjective evaluation of MAC
Number of subjects: 61
Study 10688339 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin 'A'
Number of subjects: 21
Study 9180113 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine plus aspirin
Number of subjects: 47
Study 9180113 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 47
Study 1336898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg doses of oral etoposide given twice daily for 14 days every 3 weeks
Number of subjects: 78
Study 1336898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg doses of oral etoposide given once daily for 21 days every 4 weeks
Number of subjects: 78
Study 1336898 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-mg doses of oral etoposide given twice daily for 10 days every 3 weeks
Number of subjects: 78
Study 3994433 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin 1 gm every 4 hours (C)
Number of subjects: 257
Study 3994433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole 1 gm every 4 hours (M)
Number of subjects: 257
Study 3994433 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin 600 mg every 6 hours and Tobramycin 1.2 mg/kg every 6 hours (CT)
Number of subjects: 257
Study 3994433 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin/Tobramycin (CT)
Number of subjects: 257
Study 3994433 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefamandole (M)
Number of subjects: 257
Study 3994433 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin (C)
Number of subjects: 257
Study 3994433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay (CT)
Number of subjects: 257
Study 3994433 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay (M)
Number of subjects: 257
Study 3994433 — intervention group
Group type: COMPARATOR
Intervention: Hospital stay (C)
Number of subjects: 257
Study 30912767 — intervention group
Group type: COMPARATOR
Intervention: Circulating lymphocytes with identified genes LEF1, FASLG, and MMP9
Number of subjects: 0
Study 30912767 — intervention group
Group type: COMPARATOR
Intervention: Pan-cancer and pan-pathology failed immune response profiles
Number of subjects: 0
Study 30912767 — intervention group
Group type: COMPARATOR
Intervention: Non-invasive diagnostic markers
Number of subjects: 0
Study 28925801 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted trivalent influenza vaccine FLUAD® (aTIV)
Number of subjects: 287
Study 28925801 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted trivalent influenza vaccine (TIV)
Number of subjects: 287
Study 28925801 — intervention group
Group type: EXPERIMENTAL
Intervention: Both aTIV and TIV
Number of subjects: 287
Study 27269416 — intervention group
Group type: EXPERIMENTAL
Intervention: Povidone Iodine (PVI) solution used to cleanse skin around wounds
Number of subjects: 444
Study 27269416 — intervention group
Group type: COMPARATOR
Intervention: Normal saline irrigation (control)
Number of subjects: 444
Study 24619324 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway‐based intervention
Number of subjects: 40
Study 24619324 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 40
Study 21958937 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-navigated arthroplasty
Number of subjects: 71
Study 21958937 — intervention group
Group type: COMPARATOR
Intervention: Conventional arthroplasty
Number of subjects: 71
Study 20386119 — intervention group
Group type: EXPERIMENTAL
Intervention: High-load low repetitions (HLLR)
Number of subjects: 18
Study 20386119 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-load high repetitions (LLHR)
Number of subjects: 18
Study 20386119 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 18
Study 19192102 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted Referral intervention
Number of subjects: 66516
Study 19192102 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 66516
Study 15700313 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenretinide daily for 1 year
Number of subjects: 170
Study 15700313 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 170
Study 12825106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil 50 mg (adjustable to 100 or 25 mg)
Number of subjects: 254
Study 12825106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 254
Study 10844380 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with CAD (n = 213)
Number of subjects: 337
Study 10844380 — intervention group
Group type: COMPARATOR
Intervention: Men without CAD (n = 124)
Number of subjects: 337
Study 10844380 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with CAD
Number of subjects: 337
Study 7552520 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + zalcitabine (ddC) + saquinavir
Number of subjects: 225
Study 7552520 — intervention group
Group type: EXPERIMENTAL
Intervention: AZT + ddC + nevirapine
Number of subjects: 225
Study 7552520 — intervention group
Group type: COMPARATOR
Intervention: AZT + ddC
Number of subjects: 225
Study 1819547 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH), 0.1 U/kg daily (group A)
Number of subjects: 22
Study 1819547 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH), 0.1 U/kg daily plus oxandrolone, 0.06 mg/kg (group B)
Number of subjects: 22
Study 6756151 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Number of subjects: 100
Study 6756151 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Number of subjects: 100
Study 6756151 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose estrogen (17 beta-estradiol and estriol with norethisterone acetate)
Number of subjects: 100
Study 6756151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 30845936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention for teachers consisting of 'A Healthy Start' and 'PLAYgrounds for Toddlers' programs.
Number of subjects: 249
Study 29187412 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin self‐monitoring (SSM) smartphone 'App' with standard written advice on skin cancer detection and sun protection.
Number of subjects: 200
Study 29187412 — intervention group
Group type: COMPARATOR
Intervention: Standard written advice alone (control group).
Number of subjects: 200
Study 27213635 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT (9 face-to-face sessions, supplemented with digital support via tablet and 3 e-mail contacts)
Number of subjects: 36
Study 27213635 — intervention group
Group type: COMPARATOR
Intervention: Regular CBT (12 weekly sessions)
Number of subjects: 36
Study 27213635 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended CBT
Number of subjects: 36
Study 27213635 — intervention group
Group type: COMPARATOR
Intervention: Regular CBT
Number of subjects: 36
Study 24381293 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall spectral range of acoustic stimulation
Number of subjects: 0
Study 24381293 — intervention group
Group type: EXPERIMENTAL
Intervention: Spectral spacing of acoustic stimulation
Number of subjects: 0
Study 22559091 — intervention group
Group type: EXPERIMENTAL
Intervention: Written HPV pamphlet
Number of subjects: 200
Study 22559091 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV video
Number of subjects: 200
Study 22559091 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 19354332 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% ointment
Number of subjects: 10
Study 19354332 — intervention group
Group type: COMPARATOR
Intervention: Petroleum emollient (control)
Number of subjects: 10
Study 17639748 — intervention group
Group type: EXPERIMENTAL
Intervention: Local periodontal therapy
Number of subjects: 50
Study 17639748 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 15642809 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical 0.5% timolol treatment for 3 years
Number of subjects: 21
Study 15642809 — intervention group
Group type: COMPARATOR
Intervention: Primary argon laser trabeculoplasty
Number of subjects: 21
Study 12372573 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous amiodarone (150 mg bolus)
Number of subjects: 29
Study 12372573 — intervention group
Group type: COMPARATOR
Intervention: Intravenous lidocaine (100 mg bolus)
Number of subjects: 29
Study 9987702 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/d) for 1 day
Number of subjects: 20
Study 9987702 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (4 g/d) for 2 weeks
Number of subjects: 20
Study 9987702 — intervention group
Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 20
Study 7582676 — intervention group
Group type: EXPERIMENTAL
Intervention: Valine (30 g)
Number of subjects: 12
Study 2248070 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 64
Study 2248070 — intervention group
Group type: COMPARATOR
Intervention: Clomipramine
Number of subjects: 64
Study 7016449 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (DS 103-282)
Number of subjects: 21
Study 7016449 — intervention group
Group type: COMPARATOR
Intervention: Baclofen
Number of subjects: 21
Study 31640977 — intervention group
Group type: EXPERIMENTAL
Intervention: Daptomycin plus ceftaroline (combination therapy)
Number of subjects: 40
Study 31640977 — intervention group
Group type: COMPARATOR
Intervention: Standard of care monotherapy (control)
Number of subjects: 40
Study 27889843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambu AuraGain
Number of subjects: 60
Study 27889843 — intervention group
Group type: COMPARATOR
Intervention: LMA Supreme
Number of subjects: 60
Study 25481378 — intervention group
Group type: EXPERIMENTAL
Intervention: As-needed budesonide and formoterol therapy
Number of subjects: 866
Study 25481378 — intervention group
Group type: COMPARATOR
Intervention: Regular budesonide and formoterol therapy
Number of subjects: 866
Study 23675619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsating electromagnetic field (PEMF) therapy (15 min exposure, low-frequency PEMF, 5 days/week for 12 weeks)
Number of subjects: 54
Study 23675619 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 54
Study 21843027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with RelyX ARC
Number of subjects: 880
Study 21843027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with Panavia 21
Number of subjects: 880
Study 21843027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with RelyX Unicem
Number of subjects: 880
Study 21843027 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluma Desensitizer with G-Cem
Number of subjects: 880
Study 21843027 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive cements without Gluma Desensitizer
Number of subjects: 880
Study 21843027 — intervention group
Group type: COMPARATOR
Intervention: Conventional cement (RelyX ARC)
Number of subjects: 880
Study 21843027 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-adhesive cements with and without desensitizer
Number of subjects: 880
Study 19526754 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenfu Injection (SFI) given once a day at a dose of 40 mL after dilution for one week.
Number of subjects: 63